ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
Baird Maintains Outperform on YETI Holdings, Lowers Price Target to $70
Baird analyst Peter Benedict maintains YETI Holdings (NYSE:YETI) with a Outperform and lowers the price target from $90 to $70.